ALPMY
Price:
$9.63
Market Cap:
$2.74T
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are im...[Read more]
Industry
Drug Manufacturers - General
IPO Date
2009-12-29
Stock Exchange
PNK
Ticker
ALPMY
According to Astellas Pharma Inc.’s latest financial reports and current stock price. The company's current ROE is 3.47%. This represents a change of 300.27% compared to the average of 0.87% of the last 4 quarters.
The mean historical ROE of Astellas Pharma Inc. over the last ten years is 11.35%. The current 3.47% ROE has changed -69.40% with respect to the historical average. Over the past ten years (40 quarters), ALPMY's ROE was at its highest in in the December 2018 quarter at 6.78%. The ROE was at its lowest in in the March 2023 quarter at -3.06%.
Average
11.35%
Median
11.65%
Minimum
1.07%
Maximum
17.66%
Discovering the peaks and valleys of Astellas Pharma Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 49.21%
Maximum Annual ROE = 17.66%
Minimum Annual Increase = -83.69%
Minimum Annual ROE = 1.07%
Year | ROE | Change |
---|---|---|
2024 | 1.07% | -83.69% |
2023 | 6.55% | -22.96% |
2022 | 8.50% | -2.33% |
2021 | 8.70% | -42.61% |
2020 | 15.16% | -14.18% |
2019 | 17.66% | 36.03% |
2018 | 12.98% | -24.49% |
2017 | 17.20% | 11.80% |
2016 | 15.38% | 49.21% |
2015 | 10.31% | 43.89% |
The current ROE of Astellas Pharma Inc. (ALPMY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
5.37%
5-year avg
7.99%
10-year avg
11.35%
Astellas Pharma Inc.’s ROE is greater than Bristol-Myers Squibb Company PFD CONV 2 (-36.26%), less than Daiichi Sankyo Company, Limited (0%), less than AstraZeneca PLC (15.13%), less than Astellas Pharma Inc. (16.57%), less than Bayer Aktiengesellschaft (3.47%), greater than Otsuka Holdings Co., Ltd. (-2.61%), less than Pfizer Inc. (6.04%), less than Luye Pharma Group Ltd. (4.72%), less than Sanofi (6.03%), less than Amarin Corporation plc (6.13%), greater than Novartis AG (-7.22%), less than null (41.08%),
Company | ROE | Market cap |
---|---|---|
-36.26% | $116.78B | |
0% | $51.38B | |
15.13% | $203.28B | |
16.57% | $18.38B | |
3.47% | $19.10B | |
-2.61% | $29.19B | |
6.04% | $150.52B | |
4.72% | $1.42B | |
6.03% | $121.05B | |
6.13% | $185.11M | |
-7.22% | $192.21B | |
41.08% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Astellas Pharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Astellas Pharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Astellas Pharma Inc.'s ROE?
How is the ROE calculated for Astellas Pharma Inc. (ALPMY)?
What is the highest ROE for Astellas Pharma Inc. (ALPMY)?
What is the 3-year average ROE for Astellas Pharma Inc. (ALPMY)?
What is the 5-year average ROE for Astellas Pharma Inc. (ALPMY)?
How does the current ROE for Astellas Pharma Inc. (ALPMY) compare to its historical average?